Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REIMAGINE2: CagriSema vs semaglutide vs cagrilintide in type 2 diabetes on metformin ± SGLT2 inhibitor
jRCT2031230369Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2023
- Modality
- Peptides
01
Overview
Randomised, double-blind trial of CagriSema in type 2 diabetes mellitus (T2DM) (7 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c from baseline to end of treatment. Started Sep 2023; status: completed.
02
Drugs
CagriSema
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2031230369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230369.